Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy EXPERT REVIEW OF HEMATOLOGY 2018
Association between proteomic profile and molecular response in chronic myeloid leukemia patients LEUKEMIA & LYMPHOMA 2018
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series ANNALS OF HEMATOLOGY 2018
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project QUALITY OF LIFE RESEARCH 2018
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment ANNALS OF HEMATOLOGY 2018
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study HEMATOLOGICAL ONCOLOGY 2018
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients LEUKEMIA RESEARCH 2018
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib EXPERT OPINION ON DRUG SAFETY 2018
Mechanisms And Clinical Course Of Cardiovascular Toxicity Of Cancer Treatments: Bcr/Abl1 Kinase Inhibitors CHEMOTHERAPY 2018
Patient-Reported Outcomes Enhance the Survival Prediction of Traditional Disease Risk Classifications: An International Study in Patients With Myelodysplastic Syndromes CANCER 2018
Residual Peripheral Blood CD26(+) Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission FRONTIERS IN ONCOLOGY 2018
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera. A retrospective analysis of 623 PTS With long follow-up LEUKEMIA RESEARCH 2018
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis AMERICAN JOURNAL OF HEMATOLOGY 2018
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice ANNALS OF HEMATOLOGY 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients BRITISH JOURNAL OF HAEMATOLOGY 2018
Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy ANNALS OF HEMATOLOGY 2018
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse? EUROPEAN JOURNAL OF HAEMATOLOGY 2018
One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience BLOOD 2018
The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients BLOOD 2018
Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients BLOOD 2018

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma